Page 312 - 2021_04-Haematologica-web

1228
haematologica | 2021; 106(4)
ERRATA CORRIGE
A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome
Meral Beksac,1 Guldane Cengiz Seval,1 Nicholas Kanellias,2 Daniel Coriu,3 Laura Rosiñol,4 Gulsum Ozet,5 Vesselina Goranova-Marinova,6 Ali Unal,7 Jelena Bila,8 Hayri Ozsan,9 Arben Ivanaj,10 Lejla Ibricevic Balić,11 Efstathios Kastritis,2 Joan Bladé,4 Meletios Athanasios Dimopoulos2
1Department of Hematology, School of Medicine, Ankara University, Ankara, Turkey; 2Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece; 3University of Medicine and Pharmacy "Carol Davila", Fundeni Clinical Institute, Bucharest, Romania; 4Hospital Clinic, IDIBAPS, Barcelona, Spain; 5Clinic of Hematology, Ankara Numune Education and Research Hospital, Ankara, Turkey; 6University Hospital “Sv. Georgi” and Medical University Plovdiv, Plovdiv, Bulgaria; 7Department of Hematology, School of Medicine, Erciyes University, Kayseri, Turkey; 8Faculty of Medicine, University of Belgrade, Belgrade, Serbia; 9Department of Hematology, School of Medicine, Dokuz Eylül University, Izmir, Turkey; 10University of Medicine Tirana, Tirana, Albania and 11Clinical Center of Sarajevo University, Sarajevo, Bosnia and Herzegovina
Published in Haematologica 2020;105(1):201-208.
doi:10.3324/haematol.2020.278272
©2021 Ferrata Storti Foundation
We have noticed an error in the progression-free survival of patients with extramedullary plasmacytoma in our article published in Haematologica in January 2020 (doi: HAEMATOL/2019/219295).
The following sentence in the abstract:
“Extramedullary plasmacytoma at relapse had the worst prognosis with a PFS of 13.6 months and overall survival of 11.4 months.”
Should be replaced by:
“Extramedullary plasmacytoma at relapse had the worst prognosis with a PFS of 9.1 months and overall survival of 11.4 months.”
Likewise, on page 205, the following sentence:
“However, if diagnosed at relapse, PFS and OS were 13.6 months and 11.4 months for EMP compared to 20.9 months
(P=0.249) and 39.8 months (P=0.093) for PO, respectively (Table 2 and Figure 1).”
Should be replaced by:
“However, if diagnosed at relapse, PFS and OS were 9.1 months and 11.4 months for EMP compared to 20.9 months (P=0.249) and 39.8 months (P=0.093) for PO, respectively (Table 2 and Figure 1).”
The error was also present in Table 2. The corrected Table 2 is shown below.
Table 2. Comparison of response, survival outcomes of extramedullary plasmacytomas (EMP) or paraosseous (PO) patients either at diagnosis or at relapse.
EMP
diagnosis (n=92)
relapse (n=84)
PO
diagnosis (n=38) relapse (n=12)

46.5 (95% CI: 25.5-67.5)
P<0.001
P<0.001
CR (%)
19.3 9
34.2 54.5
38.9 P<0.001 (95% CI: 23.6-54.2)
9.1 P=0.002 (95% CI: 11.6-15.6)

PFS (mos)
OS (mos)
P=0.034
11.4
(95% CI:*.6-16.2)
NR
39.8
(95% CI: 12.7-66.9)

P=0.001
51.7
95% CI: 13.5-89.9) 20.9
(95% CI: 10.3-31.5)
P=0.005
CR: complete remission; PFS: progression-free survival; OS: overall survival; n: number.